Published in Gastroenterology Week, October 30th, 2006
"From February, 2001 to September, 2002, the Southwest Oncology Group (SWOG) accrued 65 patients with advanced gastric adenocarcinoma to a phase II trial of weekly 5-FU, leucovorin, and the orally-administered uridine analog PN401. Of these 65 patients, 57 were assessable for survival and toxicity, which were the endpoints for the study," scientists in the United States reported.
"Treatment consisted of the administration of 1200 mg/m2 of 5-FU, 500 mg/m2 of leucovorin, and 6 grams of PN401 every 8 h, beginning 8 h after...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gastroenterology Week